If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...

TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...

SAN FRANCISCO, September 28, 2025 — A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

A non-DRE, voided urine, genomic assay to diagnose prostate cancer and to assess its aggressiveness. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic Classifier ...

We performed a post hoc analysis of a single-center phase II trial (ClinicalTrials.gov identifier: NCT03503643) in which patients with unilateral grade group (GG) 2-4 PCa (n = 108) underwent hemigland ...

A genomic test for successfully predicting whether cancer will resist common types of chemotherapy has been developed. Cancer Research UK (CRUK) funded scientists at the University of Cambridge (UK), ...

For decades, the story of prostate cancer screening has been dominated by three letters: P-S-A. The Prostate-Specific Antigen blood test is the first line of defense for millions of men. Yet, for all ...